pracinostat Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor based on hydroxamic acid with potential anti-tumor activity characterized by favorable physicochemical, pharmaceutical, and pharmacokinetic properties.   Wikipedia

Chemistry

  • SMILES: CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC
  • InChIKey: JHDKZFFAIZKUCU-ZRDIBKRKSA-N
  • Mol. Mass: 358.49
  • ALogP: 3.24
  • ChEMBL Molecule:
    pracinostat  
More Chemistry

Pharmacology

Alternative names

3-(2-butyl-1-(2-diethylaminoethyl)-1h-benzoimidazol-5-yl)-n-hydroxyacrylamide-hydrochloride | pracinostat | sb939 | sb939 compound

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Non-Smokers (Phase 1)

Prostatic Neoplasms (Phase 2)

Tobacco (Early Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue